VCAM1 and acute myeloid leukemia: The molecular mechanism of this drug consists of the disruption of the interaction between VLA-4 and VCAM-1 through the binding of Natalizumab to the VLA-4 α4 subunit, inducing AML cell mobilization and chemosensitivity [18].